29 patents
Page 2 of 2
Utility
Azolopyrimidine for the Treatment of Cancer-related Disorders
8 Apr 21
Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein.
Joel BEATTY, Laurent DEBIEN, Jenna JEFFREY, Manmohan Reddy LELETI, Debashis MANDAL, Dillon MILES, Jay POWERS, Brandon ROSEN, Ehesan SHARIF, Rhiannon THOMAS-TRAN
Filed: 2 Jul 19
Utility
Modulators of 5'-NUCLEOTIDASE, Ecto and the Use Thereof
6 Jan 21
Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein.
Laurent Pierre Paul DEBIEN, Juan Carlos JAEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
Filed: 31 Aug 20
Utility
Arginase Inhibitors
6 Jan 21
Compounds that are inhibitors of at least one of the ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein.
Corinne Nicole FOLEY, Rebecca Louise GRANGE, Tezcan GUNEY, Jaroslaw KALISIAK, Eric Thomas NEWCOMB, Anh Thu TRAN
Filed: 3 Mar 19
Utility
Parenterally Administered Immune Enhancing Drugs
30 Dec 20
Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein.
Juan Carlos JAEN, Jenna Leigh JEFFREY, Lixia JIN, Jaroslaw KALISIAK, Joyson J. KARAKUNNEL, M.D., Kenneth V. LAWSON, Manmohan Reddy LELETI, Jay Patrick POWERS
Filed: 7 Mar 19
Utility
Dosing with an Azolopyrimidine Compound
30 Dec 20
Joyson KARAKUNNEL, M.D.
Filed: 13 Feb 19
Utility
Inhibitors of Adenosine 5'-NUCLEOTIDASE
15 Jul 20
Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein.
Laurent Pierre Paul DEBIEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
Filed: 1 Oct 17
Utility
Quinazoline-pyridine Derivatives for the Treatment of Cancer-related Disorders
4 Mar 20
Compounds that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein.
Manmohan Reddy LELETI, Dillon Harding MILES, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF, Rhiannon THOMAS-TRAN
Filed: 2 May 18
Utility
Inhibitors of CD73-MEDIATED Immunosuppression
26 Feb 20
Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein.
Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Ehesan Ul SHARIF
Filed: 16 Nov 17
Utility
Modulators of 5'-NUCLEOTIDASE, Ecto and the Use Thereof
9 Oct 19
Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein.
Laurent Pierre Paul DEBIEN, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
Filed: 11 Feb 19